XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Revenue
3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

Note 2 Revenue

 

The Company recorded the following revenues for the three months ended March 31, 2022 and 2021:

 

  

Three Months Ended

 
  

March 31,

 
  

2022

  

2021

 

Product sales, net:

        

ORLADEYO

 $49,386  $10,938 

RAPIVAB

  160   113 

Peramivir

     6,820 

Total product sales, net

  49,546   17,871 

Royalty revenue

  347   (897)

Collaborative and other research and development revenues:

        

U.S. Department of Health and Human Services

  30   2,085 

Total collaborative and other research and development revenues

  30   2,085 

Total revenues

 $49,923  $19,059